IN VITRO ACTIVITY OF QUINUPRISTIN-DALFOPRISTIN, METHICILLIN AND VANCOMYCIN AGAINST STAPHYLOCOCCUS STRAINS ISOLATED FROM CLINICAL SAMPLES

Öz

Bu çalışmada, çeşitli klinik örneklerden izole edilen stafilokok suşlarında kinupristin-dalfopristin duyarlılık oranlarının araştırılması amaçlanmıştır. Çalışmaya, mikrobiyoloji laboratuvarına gönderilen çeşitli klinik örneklerden izole edilen 98 stafilokok suşu [74'ü koagülaz negatif stafilokok (KNS) ve 24'ü S. aureus] dahil edildi. Stafilokok suşları konvansiyonel yöntemler ile tanımlandı. Stafilokok suşlarının metisilin ve kinupristin-dalfopristin duyarlılığı Clinical and Laboratory Standards Institute (CLSI) önerileri doğrultusunda Kirby-Bauer disk difüzyon yöntemiyle çalışıldı. Ayrıca suşların vankomisin duyarlılığı E-test yöntemi ile araştırıldı. Çalışmada kalite kontrol suşu olarak S. aureus ATCC 25923 kullanıldı. İzole edilen KNS’lerin 53(% 72)’ü metisiline dirençli KNS (MR-KNS) ve S. aureus’ların ise 3(%13)’ü metisiline dirençli (MRSA) olarak tanımlandı. MRKNS’lerin 8(% 15)’i kinupristin-dalfopristine dirençli iken, metisiline duyarlı KNS'lerde (MS-KNS) kinupristindalfopristin direnci 1(%5) suşta tespit edildi. MSSA ve MRSA suşlarının hiçbirinde kinupristin-dalfopristin direnci tespit edilmedi. Suşların tamamının vankomisine duyarlı olduğu bulundu. Stafilokok suşlarının kinupristindalfopristine yüksek oranda duyarlı oldukları bulundu. Sonuç olarak vankomisin gibi kinupristin-dalfopristin kombinasyonun da özellikle dirençli Gram-pozitif kok enfeksiyonlarının tedavisinde alternatif olabileceğini düşünmekteyiz

Anahtar Kelimeler

• Kinupristin-dalfopristin, metisilin, stafilokok, mikrobiyal duyarlılık testi, streptograminler

Klinik Örneklerden İzole Edilen Staphylococcus Suşlarına Karşı Kinupristin-Dalfopristin, Metisilin ve Vankomisinin in vitro Etkinliğİ

Öz

The aim of the study is to investigate susceptibility of staphylococci strains isolated from various clinical samples to quinupristin-dalfopristin. The ninety-eight strains staphylococci (CNSs) and 24 S. aureus] isolated from various clinical samples were included the study which had been sent to microbiology laboratory. Staphylococci strains were identified by using conventional methods. Methicillin and quinupristin-dalfopristin susceptibility of staphylococci strains were performed by Kirby-Bauer’s disc diffusion method according to the Clinical and Laboratory Standards Institute criteria. Also, vancomycin susceptibility of strains was investigated by E-test method. Strain of S. aureus ATCC 25923 was used as the quality control strain. The fifty-three (72%) strains of the CNSs were defined as methicillinresistant CNS (MR-CNS), three (13%) strains of S. aureus was defined as methicillin-resistant S. aureus (MRSA). The eight (15%) strains of MR-CNS were found resistant to quinupristin-dalfopristin, one (5%) strain of MS-CNS were found resistant to quinupristin-dalfopristin. None of MSSA or MRSA strains were resistant to quinupristin-dalfopristin. All of the strains were found as susceptible to vancomycin. Strains of staphylococci were found susceptible to quinupristin-dalfopristin at high rates. Consequently we think that quinupristin-dalfopristin combination may be an alternative option for treatment of resistant Gram-positive cocci infections like vancomycin

Anahtar Kelimeler

• Kinupristin-dalfopristin, metisilin, stafilokok, mikrobiyal duyarlılık testi, streptograminler.

Kaynakça

1. Ünal S. New antimicrobial agents in the treat- ment of Gram-positive infections. Ankem Derg 2008; 22:297-306.
2. Ulusoy S. Streptogramins (Quinupristin/ dalfopristin). Ankem Derg 2004; 18:174-177.
3. Ermertcan Ş. The first parenteral strepto- gramin: Quinupristin/dalfopristin. İnfeksiyon Derg 2003; 3:369-373.
4. Kang SL, Rybak MJ. In vitro bactericidal ac- tivity of Quinupristin/dalfopristin alone and in combination against resistant strains of En- terococcus species and Staphylococcus aureus. J Antimicrob Chemother 1997; 39:33-39.
5. Allington DR, Rivey MP. Quinupristin/ dalfopristin: a therapeutic review. Clin Ther 2001; 23:24-44.
6. Livermore DM. Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? J Antimicrob Chemother 2000; 46:347- 350.
7. Klastersky J. Role of Quinupristin/dalfopristin in the treatment of Gram-positive nasocomial infections in hematological or oncological patients. Cancer Treatment Reviews 2003; 29:431-440.
8. John MA, Pletch C, Hussain Z. In vitro activity of Quinupristin/dalfopristin, linezolid, telithro- mycin and comparator antimicrobial agents 13 species of coagulase-negative staphylococci. J Antimicrob Chemother 2002; 50:933-938.

9. Hwang SH, Kim MN, Pai CH, et al. In vitro activity of Quinupristin/dalfopristin and eight other antimicrobial agents against 360 clinical isolates from Korea. Yonsei Med J 2000; 41:563-569.
10. Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 2003; 36:473-481.
11. Doğanay V, Kızırgil A. In vitro activities of Quinupristin/dalfopristin and eight other antim- icrobial agents against Gram-positive cocci. FÜ Sag Bil Tıp Derg 2007; 21:129-132.
12. Doğruman-Al F, Akça G, Aykan B, et al. The susceptibility to Quinupristin/dalfopristin and Linesolid and resistance to Macrolide- Lincosamide-Streptogramin B in methicilline- resistant Staphylococcus aureus strains. Turk- ish Journal of Infection 2008; 22:153-163.
13. Öksüz L, Gürler N. In vitro susceptibility of methicillin-resistant Staphylococci isolated from clinical samples to newer antibiotics. Ankem Derg 2009; 23:71-77.